» Articles » PMID: 19723372

Aspergillus Hypersensitivity and Allergic Bronchopulmonary Aspergillosis in Patients with Bronchial Asthma: Systematic Review and Meta-analysis

Overview
Specialty Pulmonary Medicine
Date 2009 Sep 3
PMID 19723372
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The prevalence of Aspergillus hypersensitivity (AH) and allergic bronchopulmonary aspergillosis (ABPA) in bronchial asthma is reported differently in various studies.

Objective: To determine the prevalence of AH and ABPA in asthma using a systematic review.

Methods: We searched the MEDLINE and EMBASE databases for studies published from 1965 to 2008 and included studies that report the prevalence of AH/ABPA in asthma. We calculated the proportions with 95% confidence interval (CI) to assess the prevalence of AH/ABPA in the individual studies and pooled the results using a random effects model.

Results: Our search yielded 21 eligible studies. The prevalence of AH in bronchial asthma was 28% (95%CI 24-34), and was higher with an intradermal test vs. a prick test (28.7% vs. 24.8%, P = 0.002), but did not vary with the type of antigen used (indigenous or commercial). The prevalence of ABPA in bronchial asthma and Aspergillus-hypersensitive bronchial asthma was respectively 12.9% (95%CI 7.9-18.9) and 40% (95%CI 27-53). There was a wide variation in the criteria used for the diagnosis of ABPA. There was significant statistical heterogeneity assessed by the I(2) test and Cochran Q statistic in all the outcomes.

Conclusions: There is a high prevalence of AH and ABPA in patients with bronchial asthma. Careful screening should therefore be performed in all patients with bronchial asthma. Intradermal tests are more sensitive than prick tests for the diagnosis of AH. Finally, there is a need to adopt a uniform methodology and criteria for the diagnosis of AH/ABPA.

Citing Articles

Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Inhaled Voriconazole in Healthy Volunteers and Subjects With Stable Asthma.

Caponetti G, Sala F, Cervetti A, Colombo D, Tiberio E, Singh D Pharmacol Res Perspect. 2025; 13(1):e70064.

PMID: 39918069 PMC: 11803457. DOI: 10.1002/prp2.70064.


Prevalence of Aspergillus sensitization and Allergic Bronchopulmonary Aspergillosis in bronchial asthma: A systematic review of Indian studies.

Agarwal R, Muthu V, Sehgal I, Dhooria S, Prasad K, Soundappan K Lung India. 2023; 40(6):527-536.

PMID: 37961961 PMC: 10723202. DOI: 10.4103/lungindia.lungindia_69_23.


Real-World Investigation of Eosinophilic-Associated Disease Overlap (REVEAL): Analysis of a US Claims Database.

Brailean A, Kwiatek J, Kielar D, Katial R, Wang X, Xu X Allergy Asthma Immunol Res. 2023; 15(5):580-602.

PMID: 37827978 PMC: 10570778. DOI: 10.4168/aair.2023.15.5.580.


Evaluation of the Clinicoradiological Profile in Cases of Allergic Bronchopulmonary Aspergillosis: An Original Research.

Durga Pradeep G, Ajmeera R, Jha R, Medikonda M, Saifuddin R, Singh F J Pharm Bioallied Sci. 2023; 15(Suppl 1):S285-S287.

PMID: 37654414 PMC: 10466558. DOI: 10.4103/jpbs.jpbs_496_22.


Rapid onset of effect of benralizumab in a severe eosinophilic and allergic asthma patient with allergic bronchopulmonary aspergillosis.

Alaga A, Ashraff K, Din Khan N Respirol Case Rep. 2023; 11(6):e01167.

PMID: 37249921 PMC: 10209721. DOI: 10.1002/rcr2.1167.